601
Participants
Start Date
September 24, 2013
Primary Completion Date
January 7, 2015
Study Completion Date
July 7, 2016
SOF
400 mg tablet administered orally once daily
RBV
Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Peg-IFN
180 µg administered via subcutaneous injection once weekly
Grafton
Grafton
Camperdown
Westmead
Kogarah
Melbourne
Fitzroy
Heidelberg
Clayton
Hamilton
Brisbane
Woolloongabba
Greenslopes
Adelaide
Nedlands Perth
Wellington
Christchurch
New York
Binghamton
Norfolk
Marietta
Miami
Wellington
Nashville
Germantown
Novi
Saint Paul
New Orleans
Arlington
Austin
Aurora
Englewood
San Diego
Riverside
San Francisco
Seattle
Boston
Hillsborough
Newark
Nashville
Calgary
Edmonton
Vancouver
Vancouver
Vancouver
Winnipeg
Hamilton
London
Ottawa
Toronto
Toronto
Montreal
Québec
Edgbaston
Cambridge
London
London
London
London
Birmingham
Bradford
Dundee
Edinburgh
Edinburgh
Frimley
Glasgow
Glasgow
Leeds
Liverpool
London
London
Manchester
Newcastle upon Tyne
Nottingham
Oxford
Plymouth
Portsmouth
Southampton
Lead Sponsor
Gilead Sciences
INDUSTRY